Erdafitinib is a medication used to treat adults with metastatic urothelial cancer that affects the bladder or other parts of the urinary system. It is a type of targeted therapy called a kinase inhibitor. It works by blocking signals from proteins called fibroblast growth factor receptors (FGFRs) that stimulate the growth and spread of cancer cells. This helps to slow down or stop the growth of cancer cells.
Erdafitinib, also known by the brand name Balversa, is a prescription medication used to treat a specific type of bladder cancer [FDA, Balversa website]. Here's a closer look:
- Type of medication: Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor [FDA].
- Treatment: Erdafitinib targets urothelial carcinoma, a cancer that originates in the cells lining the urinary tract (bladder, ureters, and urethra) [American Cancer Society]. However, it's only effective for tumors with specific genetic alterations in the FGFR genes [FDA, Balversa website].
How it works: Erdafitinib works by blocking the activity of FGFR proteins. These proteins play a role in cell growth and division. By inhibiting FGFR, erdafitinib helps slow or stop the growth and spread of cancer cells with these specific genetic mutations [National Cancer Institute].
Usage: Erdafitinib is typically used for patients whose cancer has progressed during or after treatment with platinum-based chemotherapy medications [FDA, Balversa website]. It's usually taken orally (as a tablet) once daily [Balversa website].
Important things to know:
- Erdafitinib is not a first-line treatment for bladder cancer. It's used for patients who haven't responded well to other treatments.
- It can cause side effects like fatigue, dry mouth, diarrhea, hair loss, and changes in taste [Balversa website].
- Erdafitinib can interact with other medications, so it's crucial to inform your doctor about all medications and supplements you are taking [FDA].
- Regular blood tests are needed to monitor for potential side effects [Balversa website].
- Erdafitinib is not recommended for pregnant or breastfeeding women [FDA].
Here are some resources for further information:
- FDA: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma
- Balversa website (Erdafitinib brand information): https://www.jnj.com/media-center/press-releases/u-s-food-and-drug-administration-grants-full-approval-for-balversa-to-treat-locally-advanced-or-metastatic-bladder-cancer-with-select-genetic-alterations
- National Cancer Institute: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231807/
- American Cancer Society: https://www.cancer.org/cancer/types/bladder-cancer.html
Disclaimer: I am unable to provide medical advice. If you have any questions about erdafitinib or its use in relation to a specific condition, please consult a doctor.